Douglas Gooding

Douglas Gooding

External Management Consultant

Doug currently serves as a Business Advisor and Technical Specialist with Knowles Intellectual Property Strategies (KIPS) in Atlanta, Georgia.  In this role, Doug participates in strategy development, U.S. and international patent prosecution, licensing, patentability and freedom to operate analysis and transactional due diligence.  Doug’s areas of expertise include molecular biology, drug discovery, pre-clinical drug development, licensing, biotechnology, and early-stage venture capital investing. Doug’s experience as a life sciences investor and entrepreneur provides him with unique insight when assisting clients.

Prior to joining the firm, Doug served as President and CEO of Altiris Therapeutics.  Altiris is an early-stage biopharmaceutical company focused on the development of novel small molecule drugs that inhibit the chemokine receptor CXCR4 for use in stem cell mobilization and other indications.  Doug accepted the role with Altiris as board member and investor in a predecessor company, Metastatix, Inc., and was responsible for recapitalizing and repositioning the company with support of several of the original investors.

Prior to Altiris, Doug was the co- founder and CEO of Regado Biosciences, which went public, merged with Tobira Therapeutics and was ultimately purchased by Allergan.  Under his leadership, the company raised $50M across three venture capital financings and advanced its lead program through three Phase I studies and a Phase 2a study. Doug led the initial investment and company formation activities for Regado while a Principal at the Aurora Funds, an early-stage life sciences venture capital fund.  While at Aurora, Doug served on the Board of Directors and led investments in Regado (founding investor), Metabolon (founding investor), Cropsolution, Metastatix, and Tissue Informatics (acquired by Paradigm Genetics).

Prior to joining Aurora, Doug was a Director of Business Development at Paradigm Genetics (acquired by Clinical Data).  Doug also spent four years at Incyte Pharmaceuticals (INCY), where he was the manager of the cDNA Library Construction Group.  In addition, Doug worked as a Research Associate at Stratagene Cloning Systems in La Jolla, California.

Doug is actively involved in the life sciences community in the Southeast region, including leadership roles with the BioMed Investors Network and Southeast BIO (SEBIO).  In connection with both, he is involved in identifying and screening promising life sciences companies seeking angel and venture investment.

Doug received a Bachelor of Arts in Biology, with a minor in Chemistry, from the University of San Diego and a MBA from the Kenan-Flagler Business School at the University of North Carolina in Chapel Hill, NC.